Reduced-intensity allogeneic transplantation for myeloma: reality bites
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Like a second marriage, the continued pursuit of safe and effective allogeneic stem cell transplantation for myeloma appears to be a triumph of hope over experience. In this issue of Blood , Bruno et al[1][1] and Rotta et al[2][2] (along with a previous article by Rosinol et al[3][3]) describe the
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma
Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065464 · Cited by 501 · cited 1×
“For low-risk patients (absence of t(4;14), normal chromosome 13 and 17, and low beta – 2- microglobulin) treated by conventional chemotherapy followed by tandem AST, 75% are alive at 5 years.”
Method
Research works printed but not linked: 10
- Bruno, 2009, Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo., Blood, 113, 3375, 10.1182/blood-2008-07-167379 · DOI
- Rotta, 2009, Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting., Blood, 113, 3383, 10.1182/blood-2008-07-170746 · DOI
- Rosinol, 2008, A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma., Blood, 112, 3591, 10.1182/blood-2008-02-141598 · DOI · Paper page
- Garban, 2006, Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99–03 trial) with tandem autologous stem cell transplantation (IFM99–04 trial) in high-risk de novo multiple myeloma., Blood, 107, 3474, 10.1182/blood-2005-09-3869 · DOI · Paper page
- Barlogie, 2006, Thalidomide and hematopoietic-cell transplantation for multiple myeloma., N Engl J Med, 354, 1021, 10.1056/NEJMoa053583 · DOI · Paper page
- Attal, 2006, Maintenance therapy with thalidomide improves survival in patients with multiple myeloma., Blood, 108, 3289, 10.1182/blood-2006-05-022962 · DOI · Paper page
- Barlogie, 2006, Long-term outcome results of the first tandem autotransplant trial for multiple myeloma., Br J Haematol, 135, 158, 10.1111/j.1365-2141.2006.06271.x · DOI · Paper page
- Lacy, 2007, Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma., Mayo Clin Proc, 82, 1179, 10.4065/82.10.1179 · DOI
- Avet-Loiseau, 2007, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome., Blood, 109, 3489, 10.1182/blood-2006-08-040410 · DOI · Paper page
- Barlogie, 2008, Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities., Blood, 112, 3115, 10.1182/blood-2008-03-145235 · DOI · Paper page
Cited by
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
“The treatment-related mortality (TRM) rate (10%–20%) and GVHD rates are fairly high.(128) Although allogenic transplantation should still be considered as investigational, it may be”
BackgroundMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24402 · Cited by 456
Myeloma today: Disease definitions and treatment advances
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24236 · Cited by 160
“In patients who live beyond the first year, high graft versus host disease (GVHD) rates even with non-myeloablative allogeneic transplantation, and likelihood of relapse remain formidable issues [94].”
Background
Metadata
- Authors
- Stewart, A. K.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-04-02
- Volume
- 113
- Issue
- 14
- Pages
- 3135-3136
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2128880706
- Cited by
- 35
- References
- 1
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced-intensity allogeneic transplantation for myeloma: reality bites. https://app.cochat.ai/papers/10.1182/blood-2008-12-173526
- The paper
- Stewart, A. K. (2009). Reduced-intensity allogeneic transplantation for myeloma: reality bites. Blood. https://doi.org/10.1182/blood-2008-12-173526
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.